Related Experiment Video

Updated: Dec 24, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.1K

Downstream Effectors of ILK in Cisplatin-Resistant Ovarian Cancer

Jeyshka M Reyes-González1, Blanca I Quiñones-Díaz1, Yasmarie Santana2

  • 1Department of Biochemistry, Medical Sciences Campus, University of Puerto Rico, San Juan, PR 00936, USA.

Cancers
|April 9, 2020
PubMed

Insights

Targeting integrin-linked kinase (ILK) shows promise for treating platinum-resistant ovarian cancer. Inhibiting ILK reduces cancer cell growth and invasion, offering new therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Ovarian cancer often relapses with platinum-resistant disease, necessitating novel therapeutic targets.
  • Integrin-linked kinase (ILK) is implicated in ovarian cancer, but its downstream effectors remain underexplored.
  • Understanding ILK's role is crucial for developing effective treatments for resistant ovarian cancer.

Purpose of the Study:

  • To investigate the molecular and biological effects of targeting ILK in cisplatin-resistant ovarian cancer.
  • To identify downstream effectors of ILK with potential prognostic and therapeutic value.
  • To evaluate ILK as a therapeutic target in platinum-resistant ovarian cancer.

Main Methods:

  • Western blot analysis to assess ILK phosphorylation levels in sensitive and resistant ovarian cancer cells.
  • Immunohistochemical analysis of ovarian cancer patient samples to correlate ILK levels with disease status.
  • Small-interfering RNA (siRNA) targeting ILK to evaluate its effects on cell growth, invasion, and apoptosis.
  • RNA sequencing (RNA-Seq) and Ingenuity Pathway Analysis (IPA) to identify ILK-regulated genes.
  • Kaplan-Meier plotter database for survival analysis of identified target genes.

Main Results:

  • Elevated ILK phosphorylation was observed in cisplatin-resistant ovarian cancer cells and patient tumors.
  • ILK inhibition via siRNA significantly reduced cell growth and invasion while increasing apoptosis in resistant cells.
  • RNA-Seq and IPA identified numerous ILK target genes, including non-coding RNAs, involved in cancer progression.
  • Survival analysis highlighted potential prognostic and therapeutic roles for these identified ILK downstream effectors.

Conclusions:

  • Integrin-linked kinase (ILK) is a promising therapeutic target for platinum-resistant ovarian cancer.
  • Targeting ILK can effectively inhibit cancer cell proliferation, invasion, and induce apoptosis.
  • Identification of ILK downstream effectors provides valuable insights into ovarian cancer pathogenesis and potential biomarkers.
Keywords:
ILKKM plotterRNA-Seqcisplatinnon-coding RNAsovarian cancersiRNA

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.6K
Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time14:25

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time

Published on: May 20, 2014

17.7K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K